



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/107, 45/06		A1	(11) International Publication Number: WO 98/51283 (43) International Publication Date: 19 November 1998 (19.11.98)
(21) International Application Number: PCT/IE98/00036 (22) International Filing Date: 14 May 1998 (14.05.98)		(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: S970346 14 May 1997 (14.05.97) IE		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): GALEN (CHEMICALS) LIMITED [IE/IE]; Belgard Road, Tallaght, Dublin 24 (IE). (72) Inventors; and (75) Inventors/Applicants (for US only): PASSMORE, Clare [GB/GB]; 108 Malone Road, Belfast (GB). GILLIGAN, Claire [GB/GB]; 17 Orpen Park, Belfast (GB).			
(74) Agents: O'CONNELL, Maura et al.; F. R. Kelly & Co. 9 University Street, Belfast BT7 1NA (GB).			

(54) Title: TOPICAL COMPOSITIONS

(57) Abstract

The invention concerns a topical composition comprising an emulsion of at least one discontinuous phase in a continuous phase, the or each discontinuous phase including a eutectic mixture of first and second pharmacologically active agents and the continuous phase being provided by a pharmaceutically acceptable carrier, the eutectic mixture having a melting point below 40 °C. The topical composition may additionally comprise, in the eutectic mixture, a third or fourth pharmaceutically acceptable component.